https://www.selleckchem.com/products/h-151.html
82, 95% CI 1.61-2.07) in patients with solid tumors. Although publication bias was found in the studies with regard to OS, a further trim and fill analysis revealed that the adjusted HR was 1.82 (95% CI 1.69-1.96), which was close to the original HR. Subgroup analysis confirmed the CAR as a strong prognostic marker in patients with solid tumors, regardless of the tumor type, detection time, cut-off value, sample size and area. CONCLUSION Our meta-analysis indicated that a high CAR might be an unfavorable prognostic marker for OS and DFS/P